Roswell Park’s Francisco J. Hernandez-Ilizaliturri, MD, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Dr. Hernandez-Ilizaliturri is presenting the team’s findings at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

A group of researchers led by Roswell Park's Maximillian Merz, MD, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma and is presenting the findings at ASH 2020.

Eunice Wang, MD, is leading multiple research efforts focused on different treatment approaches for acute myeloid leukemia (AML) patients. During the ASH Annual Meeting and Exposition, she is presenting data on two ongoing studies incorporating new treatment options.

Research and insights from the Roswell Park team will help to fuel three important research meetings in the week ahead as researchers in oncology, hematology and immunotherapy come together virtually for the Immunotherapy Bridge 2020 meeting, Melanoma Bridge 2020 meeting and 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Continuing to reach across international borders, Roswell Park’s Department of Indigenous Cancer Health has launched a number of educational and communications initiatives.